Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Journal Article (Journal Article)

Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.

Full Text

Duke Authors

Cited Authors

  • Bitting, RL; Armstrong, AJ; George, DJ

Published Date

  • 2011

Published In

Volume / Issue

  • 5 /

Start / End Page

  • 325 - 332

PubMed ID

  • 22084621

Pubmed Central ID

  • PMC3210626

Electronic International Standard Serial Number (EISSN)

  • 1179-5549

Digital Object Identifier (DOI)

  • 10.4137/CMO.S5977

Language

  • eng

Conference Location

  • United States